Inosine ( DrugBank: Inosine )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
6	パーキンソン病	8
13	多発性硬化症／視神経脊髄炎	2
17	多系統萎縮症	1
122	脳表ヘモジデリン沈着症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03168711 (ClinicalTrials.gov)	October 1, 2017	24/5/2017	Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Inosine;Drug: Placebo	Massachusetts General Hospital	The Salah Foundation;MGH cure ALS Fund	Completed	18 Years	85 Years	All	23	Phase 2	United States
2	JPRN-UMIN000029308	2017/07/18	30/09/2018	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of ...	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of ...	Amyotrophic lateral sclerosis	Febuxostat 20 mg, Inosine 500 mg, twice a day for 14 days	Teikyo University	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	3	Not applicable	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
4	NCT02288091 (ClinicalTrials.gov)	January 2015	5/11/2014	A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)	A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Inosine	Massachusetts General Hospital	The Salah Foundation;MGH cure ALS Fund	Completed	18 Years	N/A	All	32	Phase 1	United States

First Previous1Next Last

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat ...	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Complete	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
2	JPRN-UMIN000030930	2018/01/29	01/01/2019	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosineof patients wi ...	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosineof patients wi ...	Parkinson's disease	Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days	StaGen Co. Ltd.	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	30	Not selected	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
4	NCT02642393 (ClinicalTrials.gov)	June 2016	19/12/2015	Study of Urate Elevation in Parkinson's Disease, Phase 3	A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating InosineTreatment to Slow Cli ...	Parkinson's Disease	Drug: Inosine;Drug: Placebo	Michael Alan Schwarzschild	The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester ...	Completed	30 Years	N/A	All	298	Phase 3	United States;Puerto Rico
5	JPRN-UMIN000009062	2016/05/30	09/10/2012	An open-label, single-centered, non-randomized trial of inosineto assess its safety for patients wit ...	An open-label, single-centered, non-randomized trial of inosineto assess its safety for patients wit ...	Parkinson's disease	Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL	Dept. of Clinical pharmacology and Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Phase 1	Japan
6	JPRN-jRCTs061180060	22/03/2016	18/03/2019	Randomized clinical trial to assess the disease modifying effect of oral inosinefor patients with Pa ...	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Parkinson's disease;D010300	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)	Nagai Masahiro	NULL	Complete	>= 20age old	Not applicable	Both	100	Phase 2	Japan
7	JPRN-UMIN000020527	2016/02/01	01/02/2016	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Parkinson's disease	Inosineto maintain a serum urate level between 6.0-7.5 mg/dL for 2 years Lactose as a placebo for 2 y ...	Ehime University Graduate School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	100	Phase 2	Japan
8	NCT00833690 (ClinicalTrials.gov)	June 2009	27/1/2009	Safety of Urate Elevation in Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosineto Assess Safety a ...	Parkinson Disease	Drug: Placebo;Drug: inosine	The Parkinson Study Group	Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fo ...	Completed	30 Years	N/A	All	75	Phase 2	United States

First Previous1Next Last

先頭へ

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
2	NCT00067327 (ClinicalTrials.gov)	February 2002	15/8/2003	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Multiple Sclerosis, Relapsing-Remitting	Drug: Inosine	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	18 Years	60 Years	Both	30	Phase 2	United States

First Previous1Next Last

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03403309 (ClinicalTrials.gov)	May 2, 2018	11/1/2018	Inosine5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: ...	Inosine5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: ...	Multiple System Atrophy	Drug: 1) Inosine 5'-monophosphate;Drug: Placebo	Yonsei University	NULL	Completed	19 Years	75 Years	All	43	Phase 2	Korea, Republic of

First Previous1Next Last

122. 脳表ヘモジデリン沈着症

臨床試験数 : 3 / 薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04890808 (ClinicalTrials.gov)	May 2023	12/5/2021	Therapeutic Antioxidant Supplementation	Therapeutic Antioxidant Supplementation for Enhancement of Neural Protection From Free-iron Toxicity ...	Superficial Siderosis	Dietary Supplement: Inosine;Dietary Supplement: IP6	Superficial Siderosis Research Alliance Inc.	NULL	Not yet recruiting	16 Years	77 Years	All	50	N/A	NULL

First Previous1Next Last

先頭へ